Trial Profile
A exploratory controlled clinical study of Apatinib combined TACE in treating advanced hepatocellular carcinoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Oct 2016
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 20 Oct 2016 New trial record